No. Gleevec (imatinib) is a targeted cancer therapy, which means that it is only effective against cancer cells with a particular genetic mutation. It will not be effective against cancer cells without the mutation.
Some exceptions. There are a very few number of patients who benefit from Gleevec (imatinib) that have other, rarer mutations of associated genes. Talk to your oncologist about your particular case.